BIVI - Investigation Into BioVie Inc. (BIVI) Announced by Holzer & Holzer LLC | Benzinga
ATLANTA, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether BioVie Inc. ("BioVie" or the "Company") (NASDAQ:BIVI) complied with federal securities laws. On November 29, 2023, BioVie Inc. announced topline efficacy data from its Phase 3 clinical trial of NE3107 and revealed that "the Company found significant deviation from protocol and Good Clinical Practice (GCP) violations at 15 sites (virtually all of which were from one geographic area). This highly unusual level of suspected improprieties led the Company to exclude all patients ...
BIVI) Announced by Holzer & Holzer, LLC>Full story available on Benzinga.com